Insulin is a protein hormone secreted by islet beta cells in the pancreas; it is the only hormone in the body that lowers blood sugar. At the same time, insulin has the function of promoting the synthesis of glycogen, fat and protein. Insulin is involved in the regulation of glucose metabolism, and the blood sugar balance is controlled. The decrease in insulin secretion leads to an increase in blood glucose concentration in the body, leading to diabetes.
With the improvement of people's living standards, the global incidence of diabetes has increased rapidly. The incidence of diabetes in China also shows a rapid growth trend. According to the International Diabetes Federation (IDF), the number of people with diabetes is increasing rapidly around the world. In 2013, the number of people with diabetes worldwide reached 382 million. It is estimated that by 2035, this number will reach 592 million. There are 92.4 million diabetic patients in China, ranking first in the world. With the improvement of national health insurance policy and policies, the acceleration of an aging society, the promotion of expert education, the change of insulin use concept, the strengthening of self-care and the rapid development of recombinant human insulin, the domestic insulin has been accelerated. The market is growing rapidly.
The rapid development of the market has brought unprecedented opportunities for domestic insulin companies, and important contributions such as recombinant insulin glargine, insulin aspart, recombinant human insulin, and insulin lispro have made important contributions. In the domestic insulin market is still the world of foreign brands, but the domestic insulin industry is beginning to take shape, and opening the market is just around the corner.